Surface Oncology, Inc.
SURF · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $30 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $30 | $0 |
| % Margin | – | – | 100% | – |
| R&D Expenses | $14 | $14 | $15 | $17 |
| G&A Expenses | $9 | $6 | $6 | $6 |
| SG&A Expenses | $9 | $6 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22 | $20 | $21 | $23 |
| Operating Income | -$26 | -$20 | -$21 | -$23 |
| % Margin | – | – | -70.6% | – |
| Other Income/Exp. Net | -$3 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$28 | -$20 | -$21 | -$23 |
| Tax Expense | $0 | $1 | $0 | $0 |
| Net Income | -$28 | -$21 | -$21 | -$24 |
| % Margin | – | – | -71.6% | – |
| EPS | -0.46 | -0.34 | -0.35 | -0.4 |
| % Growth | -35.3% | 2.9% | 12.5% | – |
| EPS Diluted | -0.46 | -0.34 | -0.35 | -0.4 |
| Weighted Avg Shares Out | 61 | 61 | 61 | 59 |
| Weighted Avg Shares Out Dil | 61 | 61 | 61 | 59 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $1 | $0 | $1 |
| Depreciation & Amortization | $2 | $1 | $0 | $1 |
| EBITDA | -$23 | -$18 | -$29 | -$22 |
| % Margin | – | – | -96.9% | – |